Clinical and Regulatory Features of Drugs Not Initially Approved by the FDA

The FDA denied approval in the first review cycle for 52% of new drugs and biologics evaluated by FDA advisory committees between 2007 and 2009, though 63% eventually received approval by 2013, with products initially flagged for safety concerns being far more likely to achieve eventual approval (62%) compared to those with efficacy concerns (8%).